CCR2 and neoplasm: We then confirmed that treatment with the inhibitor of IDO 1-MT resulted in a recovery of the levels of plasmatic Trp in both models (Figure 4A,B) with a mild effect in tumor growth, an improvement in splenomegaly, a restoration in the levels of carbonylated proteins, and a decrease in CCR2 levels (receptor of MCP1), all of them linked to inflammation.